This company has been marked as potentially delisted and may not be actively trading. Cogent Biosciences (UMRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock UMRX vs. CALT, ZYME, SBTX, MBX, AVTE, NLTX, BIOA, CYBN, VIRI, and WHWKShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), and Whitehawk Therapeutics (WHWK). Cogent Biosciences vs. Its Competitors Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics Cogent Biosciences (NASDAQ:UMRX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations. Does the media refer more to UMRX or CALT? In the previous week, Calliditas Therapeutics AB (publ) had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 1 mentions for Calliditas Therapeutics AB (publ) and 0 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.00 beat Calliditas Therapeutics AB (publ)'s score of -0.71 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Overall Sentiment Cogent Biosciences Neutral Calliditas Therapeutics AB (publ) Negative Which has higher earnings & valuation, UMRX or CALT? Cogent Biosciences has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent Biosciences$22.50M23.90-$31.83M-$1.04-12.17Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Do institutionals and insiders hold more shares of UMRX or CALT? 26.4% of Cogent Biosciences shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 31.5% of Cogent Biosciences shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is UMRX or CALT more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Cogent Biosciences' net margin of -96.84%. Cogent Biosciences' return on equity of -87.78% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Cogent Biosciences-96.84% -87.78% -52.14% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has more risk & volatility, UMRX or CALT? Cogent Biosciences has a beta of 3.93, meaning that its share price is 293% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. SummaryCogent Biosciences beats Calliditas Therapeutics AB (publ) on 9 of the 13 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UMRX vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$537.66M$833.26M$5.75B$10.24BDividend YieldN/A4.84%5.69%4.60%P/E Ratio-16.661.1874.9326.41Price / Sales23.90121.58452.3586.56Price / CashN/A19.5625.8129.91Price / Book12.176.6613.256.28Net Income-$31.83M-$4.13M$3.29B$270.38M Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UMRXCogent BiosciencesN/A$12.66-1.2%N/A+19.1%$537.66M$22.50M-16.6672CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.4835 of 5 stars$15.19-0.3%$21.43+41.1%+25.5%$1.14B$122.87M-10.13460Positive NewsSBTXSilverback TherapeuticsN/A$10.32-3.6%N/A-24.6%$372.12MN/A-4.2683High Trading VolumeMBXMBX Biosciences2.8458 of 5 stars$10.26-10.2%$37.63+266.7%N/A$344.67MN/A-2.2636Positive NewsAVTEAerovate TherapeuticsN/A$7.62+1.9%N/A-88.4%$220.87MN/A-2.5520Positive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$19.25-1.0%N/A-54.7%$180.91MN/A-6.1990BIOABioAge Labs0.2001 of 5 stars$4.82-3.2%N/AN/A$178.53MN/A0.00N/ACYBNCybin2.694 of 5 stars$6.28-2.3%$85.00+1,253.5%N/A$148.15MN/A-1.4350Gap DownVIRIVirios TherapeuticsN/A$4.83-1.4%$5.00+3.5%+2,409.0%$93.02MN/A-17.895WHWKWhitehawk Therapeutics1.1838 of 5 stars$1.79-0.6%N/AN/A$84.83M$25.98M-29.8321 Related Companies and Tools Related Companies CALT Alternatives ZYME Alternatives SBTX Alternatives MBX Alternatives AVTE Alternatives NLTX Alternatives BIOA Alternatives CYBN Alternatives VIRI Alternatives WHWK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UMRX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
